Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib

In the last decade, there have been major therapeutic advances in the management of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. Crizotinib was the first approved ALK inhibitor with significant benefits over chemotherapy. However, patients inevitably develop di...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Rohit K, Chen, Hongbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648304/
https://www.ncbi.nlm.nih.gov/pubmed/29075144
http://dx.doi.org/10.2147/LCTT.S126507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648304/
https://www.ncbi.nlm.nih.gov/pubmed/29075144
http://dx.doi.org/10.2147/LCTT.S126507

Ejemplares similares